Functional roles and nutritional potential of human milk oligosaccharides in swine gut health.

A Comprehensive Review of Fucosylated Human Milk Oligosaccharides: Biological Functions, Production Technologies, and Safety Regulation With Commercial Translation in Infant Nutrition.

Human milk oligosaccharides (HMOs) are important functional bioactive components of human milk. Fucosylated HMOs (FHMOs) represent a major subclass, accounting for approximately 35%-50% of total HMOs, and have attracted increasing attention in infant nutrition and health. Current evidence indicates that FHMOs play important roles in shaping the infant gut microbiota, modulating host-microbe interactions, supporting intestinal barrier function, and maintaining immune and metabolic homeostasis. However, their commercialization still faces several challenges, including high production costs, difficulties in the scalable manufacture of structurally complex members, uneven functional evidence across individual compounds, incomplete safety and regulatory evaluation frameworks, and the need to further validate processing stability and application performance in final products. From an industrial perspective, microbial fermentation has become the main production route for 2'-fucosyllactose and 3-fucosyllactose, whereas the large-scale production of more structurally complex or low-abundance FHMOs remains technically and economically challenging. Regulatory approvals in major markets indicate acceptable safety at authorized use levels, but uncertainties remain regarding long-term intake, vulnerable infant populations, matrix-dependent stability, and the combined use of multiple HMOs. This review summarizes recent advances in the structural characteristics, biological functions, production technologies, safety assessment, regulatory status, and commercial applications of FHMOs, with emphasis on 2'-fucosyllactose, 3-fucosyllactose, and selected structurally related members. It also discusses commercialization challenges and future research priorities to support their responsible application in infant nutrition.

The impact of human milk oligosaccharides and galacto-oligosaccharides on the growth of early life pathogenic gut bacteria

Antibiotics are widely used to prevent and treat early life gut infections, but their aberrant use has raised global concerns about antibiotic resistance. As breastfed infants have fewer intestinal infections than formula-fed infants, this stimulated scientific interest in the anti-pathogenic properties of breastmilk, specifically human milk oligosaccharides (HMOs). HMOs are non-digestible sugars that support infant gut microbiome development, immune maturation, and protection against pathogens. However, to determine how specific HMO structures differentially affect microbial growth and pathogen susceptibility investigating individual HMOs is essential. This study therefore evaluates the effects of single-structure HMOs and galacto-oligosaccharides (GOS) on the growth of key early-life gut pathogens, Escherichia coli, Salmonella enterica, Yersinia enterocolitica, and Clostridium perfringens. The strongest pathogen inhibitory effects of HMOs were further assessed by colony forming unit enumeration and tested across variable media to confirm oligosaccharide-specific efficacy. Oligosaccharide screening revealed clear differences in bacterial growth, with S. enterica most strongly inhibited and C. perfringens exhibiting growth stimulation. Among the tested oligosaccharides, 3′-galactosyllactose and GOS showed the most pronounced growth-inhibitory effects against Escherichia coli, Salmonella enterica, Yersinia enterocolitica. Salt concentration and nutrient richness further modulated oligosaccharide activity, highlighting the multifactorial nature of their antibacterial potential. Overall, our findings show that oligosaccharides display structure-specific and environment-dependent effects on bacterial growth, indicating that their antimicrobial activity is shaped by oligosaccharide structure, bacterial species, and growth environment.

Implementation of human milk antimicrobial peptides for immune protection in formula feeding

Human milk is widely recognized as the biological standard for early-life nutrition, providing both essential nutrients and bioactive components that support immune development. However, breastfeeding is not always feasible, and infant formula remains a necessary alternative in specific clinical and social contexts. Despite advances in formulation, significant immunological differences persist between breastfed and formula-fed infants, contributing to the so-called “immunological gap.” This review critically examines the potential of human milk-derived antimicrobial peptides (HM-AMPs) as functional ingredients to partially address this gap. Current evidence indicates that these peptides, derived from proteins such as lactoferrin, caseins, and α-lactalbumin, exhibit antimicrobial and immunomodulatory activities through mechanisms including membrane disruption and modulation of inflammatory pathways. However, most available data are derived from in vitro and preclinical models, limiting direct translation to clinical outcomes. In addition, significant challenges remain, including peptide instability during industrial processing, uncertain bioavailability in the gastrointestinal tract, and limited clinical validation. While emerging computational and bioengineering strategies offer opportunities to optimize peptide functionality, their large-scale implementation remains constrained by technological and regulatory factors. Overall, HM-AMPs represent a promising but still developing approach to improving infant formula functionality. Their contribution should be interpreted as partial and context-dependent, rather than as a complete replication of the immunological properties of human milk.

Pectins and modified pectins: Bridging food technology and human health innovations.

Goat milk as a functional food: Recent advances in product development and health benefits

Goat milk occupies a distinctive niche among dairy foods by virtue of its superior digestibility, hypoallergenic nature, and dense micronutrient profile. Compared with bovine milk, caprine milk is characterised by smaller fat globules (<3.5 μm), a lower proportion of ás1-casein, an abundance of medium-chain fatty acids (caproic, caprylic, and capric acids), and highly bioavailable minerals. These attributes collectively make it a valuable dietary alternative for individuals affected by cow-milk protein allergy and gastrointestinal sensitivities. A growing body of evidence confirms the presence of bioactive peptides, prebiotic oligosaccharides, conjugated linoleic acid, taurine, and immunomodulatory compounds in goat milk, each contributing to tangible health outcomes improved gut-barrier function, cardioprotective lipid profiles, antihypertensive activity, and enhanced immune responsiveness. On the processing front, technologies such as ultrafiltration, high-pressure processing, microencapsulation, ultrasound, and probiotic fermentation have substantially elevated product quality, safety, and shelf life, facilitating diversification into cheese, yoghurt, kefir, lactose-free milk, infant formula, nutraceuticals, and cosmetic preparations. Emerging industry directions towards A2 goat-milk formulations, nanoencapsulation of bioactives, AI-assisted quality monitoring, and sustainable caprine farming which signal continued expansion of the global goat-milk sector. Despite these advances, challenges concerning low-yield breeds, seasonal supply fluctuation, limited organised-market infrastructure, and consumer-awareness gaps still warrant targeted research and policy support.

Health and Environmental Implications of Alternative Proteins in Human Diets: Nutritional Value, Gut Microbiota Modulation, and Sustainability Perspectives

Overall, alternative proteins represent a promising pathway toward sustainable food system transformation, but their successful integration will depend on evidence-based development, improved processing strategies, standardized evaluation, and supportive policy frameworks.